Author Interviews, Cannabis, JAMA, UCSD / 23.10.2019
Online Searches for CBD Skyrocket
MedicalResearch.com Interview with:
[caption id="attachment_51918" align="alignleft" width="158"]
Dr. Ayers[/caption]
John W. Ayers, PhD, MA
Vice Chief of Innovation | Assoc. Professor
Div. Infectious Disease & Global Public Health
University of California San Diego
MedicalResearch.com: What is the background for this study?
Response: Touted as a “cure all,” researchers have documented unfounded claims
that cannabidiol (CBD) treats acne, anxiety, opioid addiction, pain,
and menstrual problems. You can buy CBD droplets, massage oils,
CBD gummies, or even ice cream.
But public health leaders have been mostly silent on the subject because they lacked data
that demonstrates just how popular CBD is and the future trajectory might be.
To fill this data-gap we analyzed Google search queries that mentioned
“CBD” or “cannabidiol” emerging from the United States from January
2004 through April 2019 and forecasted searches through December 2019.
Rather than relying on self reports, where some might not be willing
to discuss CBD openly, our strategy allowed us to directly observed
millions of instances of people seeking out information or even
shopping for CBD online.
Dr. Ayers[/caption]
John W. Ayers, PhD, MA
Vice Chief of Innovation | Assoc. Professor
Div. Infectious Disease & Global Public Health
University of California San Diego
MedicalResearch.com: What is the background for this study?
Response: Touted as a “cure all,” researchers have documented unfounded claims
that cannabidiol (CBD) treats acne, anxiety, opioid addiction, pain,
and menstrual problems. You can buy CBD droplets, massage oils,
CBD gummies, or even ice cream.
But public health leaders have been mostly silent on the subject because they lacked data
that demonstrates just how popular CBD is and the future trajectory might be.
To fill this data-gap we analyzed Google search queries that mentioned
“CBD” or “cannabidiol” emerging from the United States from January
2004 through April 2019 and forecasted searches through December 2019.
Rather than relying on self reports, where some might not be willing
to discuss CBD openly, our strategy allowed us to directly observed
millions of instances of people seeking out information or even
shopping for CBD online.
Dr. Helen Marsden PhD
Skin Analytics Limited
London, United Kingdom
MedicalResearch.com: What is the background for this study?
Response: In this technology age, with the explosion of interest and applications using Artificial Intelligence, it is easy to accept the output of a technology-based test - such as a smartphone app designed to identify skin cancer - without thinking too much about it. In reality, technology is only as good as the way it has been developed, tested and validated. In particular, AI algorithms are prone to a lack of “generalisation” - i.e. their performance drops when presented with data it has not seen before. In the medical field, and particularly in areas where AI is being developed to direct a patient’s diagnosis or care, this is particularly problematic. Inappropriate diagnosis or advice to patients can lead to false reassurance, heightened concern and pressure on NHS services, or worse. It is concerning, therefore, that there are a large number of smartphone apps available that provide an assessment of skin lesions, including some that provide an estimate of the probability of malignancy, that have not been assessed for diagnostic accuracy.
Skin Analytics has developed an AI-based algorithm, named: Deep Ensemble for Recognition of Malignancy (DERM), for use as a decision support tool for healthcare providers. DERM determines the likelihood of skin cancer from dermoscopic images of skin lesions. It was developed using deep learning techniques that identify and assess features of these lesions which are associated with melanoma, using over 7,000 archived dermoscopic images. Using these images, it was shown to identify melanoma with similar accuracy to specialist physicians. However, to prove the algorithm could be used in a real life clinical setting, Skin Analytics set out to conduct a clinical validation study.

Dr. Hongying (Daisy) Dai[/caption]
Hongying (Daisy) Dai, PhD
Associate Professor
Department of Biostatistics | College of Public Health
University of Nebraska Medical Center
MedicalResearch.com: What is the background for this study?
Response: Although marijuana is still classified as a Schedule I drug at the Federal level, as of June 2019, 33 states and the District of Columbia have legalized one or more forms of marijuana; 11 states and the District of Columbia have approved both medical and recreational uses. Public opinion on marijuana has changed dramatically over the last two decades and support for legalization has doubled since 2010. However, very little is known about the prevalence and patterns of marijuana use among adults with medical conditions.
This study analyzed the 2016 and 2017 Behavioral Risk Factor Surveillance System data to report the prevalence and patterns of marijuana use among adults with self-reported medical conditions.
